Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial

There is a real unmet need for primary biliary cholangitis (PBC) treatments that can improve quality of life impacting symptoms. In this post hoc analysis, we evaluated potential effects of the NADP oxidase 1/4 inhibitor, setanaxib, on patient-reported quality of life from a phase 2 trial in PBC. PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, David, Carbone, Marco, Invernizzi, Pietro, Little, Nicola, Nevens, Frederik, Swain, Mark G., Wiesel, Philippe, Levy, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949832/
https://www.ncbi.nlm.nih.gov/pubmed/36809195
http://dx.doi.org/10.1097/HC9.0000000000000057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949832/
https://www.ncbi.nlm.nih.gov/pubmed/36809195
http://dx.doi.org/10.1097/HC9.0000000000000057

Ejemplares similares